Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4FRONT-2: Single Intravitreal Injection of 4D-150 vs Aflibercept in nAMD
jRCT2073250103Phase 3Recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Apr 2026
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of 4D-150 in exudative macular degeneration (2 arms), sponsored by 4D Molecular Therapeutics. Primary endpoint: Mean change from baseline in BCVA ETDRS letter score at Week 52. Started Apr 2026; status: recruiting.
02
Drugs
4D-150
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2073250103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073250103.